Loading...
ROCO
6661
Market cap13mUSD
Nov 12, Last price  
18.30TWD
Name

Welgene Biotech Co Ltd

Chart & Performance

D1W1MN
ROCO:6661 chart
P/E
385.25
P/S
1.32
EPS
0.05
Div Yield, %
Shrs. gr., 5y
2.27%
Rev. gr., 5y
-5.03%
Revenues
323m
+14.97%
270,178,000277,405,000278,299,000325,776,000384,429,000417,459,000398,096,000312,650,000321,899,000280,547,000322,548,000
Net income
1m
P
21,102,00021,291,0004,094,00023,652,00028,340,00030,871,00029,774,00013,703,0009,552,000-2,648,0001,107,000
CFO
56m
P
15,805,000-9,608,0006,635,00032,259,00048,811,00085,145,00041,769,00011,246,00051,427,000-366,00056,076,000
Dividend
Mar 16, 20230.18144 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.
IPO date
Oct 23, 2017
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT